As the field of oncology continues to evolve, the potential of drugs like ganciclovir in innovative therapies remains significant. With advances in genetic engineering and delivery technologies, the precision and efficacy of ganciclovir-based therapies are expected to improve. Future research efforts will likely focus on overcoming current limitations and expanding the applicability of this approach to a broader range of cancers.
In conclusion, while ganciclovir is not a traditional cancer drug, its role in gene therapy offers a unique avenue for targeting malignancies. Continued research and clinical trials will determine its place in the arsenal against cancer, potentially providing a targeted and less toxic treatment option for patients.
